首頁 > 市場調查報告書 > 製藥

生物標記

市場調查報告書

商品編碼

1508759

神經生物標記市場：按生物標記類型、按應用、按最終用戶、按地區

Neurological Biomarkers Market, By Biomarker Type, By Application, By End User, By Geography

出版日期: 2024年06月12日 | 出版商:

Coherent Market Insights | 英文 174 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計2024年全球神經生物標記市場規模為85.1億美元，預計2031年將達201億美元，2024年至2031年複合年成長率為13.1%。

圖 1. 2024 年按地區分類的神經生物標記物市場佔有率(%)

神經生物標記有助於客觀測量和評估正常的生物和病理過程。這些生物標記物可以幫助檢測神經系統疾病、評估風險、追蹤疾病進展並測量對治療性介入的反應。阿茲海默症、帕金森氏症和多發性硬化症等神經系統疾病的發生率不斷增加，可能會推動對可靠神經生物標記的需求。此外，對神經系統疾病精準醫學和伴同性診斷開發的日益關注也推動了市場成長。然而，對疾病生物學的了解有限以及對生物標記的使用缺乏共識對市場成長構成了挑戰。

市場動態：

神經系統生物標記的全球市場成長主要是由全球神經系統疾病盛行率上升所推動的。根據世界衛生組織的資料，神經系統疾病影響全球超過10億人，使其成為全球疾病負擔的主要來源。不斷成長的老年人口更容易感染這些疾病，可能會增加需求。製藥公司增加對生物標記研究和藥物開發的投資可能會推動市場成長。然而，從標靶識別到商業化的高昂藥物開發成本阻礙了生物標記進入新興市場。關於生物標記在診斷和臨床決策中的使用缺乏共識可能會阻礙市場成長。加強跨學科研究的公私合作可能為市場成長提供機會。

本研究的主要特點

該報告對全球神經生物標記市場進行了詳細分析，並提供了以2023年為基準年的預測期（2024-2031年）的市場規模（十億美元）和年複合成長率（CAGR%）。
它還揭示了各個細分市場的潛在商機，並說明了該市場有吸引力的投資提案矩陣。
它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景、主要企業採取的競爭策略等的重要見解。
它根據公司亮點、產品系列、主要亮點、財務表現和策略等參數，介紹了全球神經生物標記物市場的主要企業。
該報告的見解使負責人和公司經營團隊能夠就未來的產品發布、升級、市場擴張和行銷策略做出明智的決策。
全球神經生物標記市場報告迎合了該行業的各種相關人員，如投資者、供應商、產品製造商、經銷商、新進業者和財務分析師。

公司簡介
- Thermo Fisher Scientific Inc.
- Merck &Co., Inc.
- Bio-Rad Laboratories, Inc.
- AbbVie Inc.
- QIAGEN NV
- F. Hoffmann-La Roche Ltd
- Siemens Healthineers AG
- Myriad RBM
- Quanterix Corporation
- PerkinElmer Inc.
- Fujirebio
- Alzheon, Inc.
- Diagenic ASA
- Psynova Neurotech Ltd
- Banyan Biomarkers, Inc.
- Cisbio Bioassays
- Athena Diagnostics
- Immuno-Biological Laboratories Co., Ltd.

第10章分析師建議

升起和降落
綜合機會圖

第11章章節

參考
調查方法

簡介目錄

Product Code: CMI4586

Global neurological biomarkers market is estimated to be valued at USD 8.51 Bn in 2024 and is expected to reach USD 20.10 Bn by 2031, exhibiting a compound annual growth rate (CAGR) 13.1% from 2024 to 2031.

Figure 1. Neurological Biomarkers Market Share (%), By Region, 2024

Neurological biomarkers help in objectively measuring and evaluating normal biological and pathogenic processes. These aid in detecting neurological disorders, assessing risk, tracking disease progression, and measuring response to therapeutic interventions. Rising incidence of neurological disorders such as Alzheimer's disease, Parkinson's disease, multiple sclerosis and others can boost demand for reliable neurological biomarkers. Furthermore, growing focus on development of precision medicine and companion diagnostics for neurological conditions can drive the market growth. However, limited understanding of disease biology and lack of consensus on use of biomarkers can pose challenge to market growth.

Market Dynamics:

Global neurological biomarkers market growth is primarily driven by rising prevalence of neurological disorders globally. According to the data from WHO, neurological disorders affect over a billion people worldwide with neurological conditions being a major contributor to the global burden of disease. Growing geriatric population, prone to these disorders, can boost demand. Higher investments in biomarker research and drug development by pharmaceutical players can drive the market growth. However, high cost of drug development from target identification to commercialization hampers newer biomarkers from entering the market. Lack of consensus on use of biomarkers in diagnosis and clinical decision-making can hamper the market growth. Increasing public private collaborations for interdisciplinary research can offer market growth opportunities.

Key Features of the Study:

This report provides in-depth analysis of the global neurological biomarkers market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global neurological biomarkers market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include F. Hoffmann-La Roche Ltd, Qiagen, Thermo Fisher Scientific and Abbott Laboratories
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global neurological biomarkers market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Detailed Segmentation-

By Biomarker Type:
- Artificial Tears
- Imaging Biomarkers
- Metabolomics Biomarkers
- Proteomic Biomarkers
- Genomics Biomarkers
By Application
- Alzheimer's Disease
- Parkinson's Disease
- Multiple Sclerosis
- Autism Spectrum Disorders
- Others
By End User
- Hospital Laboratories
- Clinical Diagnostic Centers
- Research Organizations
- Others
Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
Company Profiles:
- Thermo Fisher Scientific Inc.
- Merck & Co., Inc.
- Bio-Rad Laboratories, Inc.
- AbbVie Inc.
- QIAGEN N.V.
- Hoffmann-La Roche Ltd
- Siemens Healthineers AG
- Myriad RBM
- Quanterix Corporation
- PerkinElmer Inc.
- Fujirebio
- Alzheon, Inc.
- Diagenic ASA
- Psynova Neurotech Ltd
- Banyan Biomarkers, Inc.
- Cisbio Bioassays
- Athena Diagnostics
- Immuno-Biological Laboratories Co., Ltd.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Biomarker Type
- Market Snapshot, By Application
- Market Snapshot, By End User
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Opportunities
Impact Analysis
Market Trends
Key Developments
Regulatory Scenario
Acquisitions and Partnerships Scenario
Funding and Investments
PEST Analysis
Porter's Analysis

4. Global Neurological Biomarkers Market - Impact of Coronavirus (COVID-19) Pandemic

Overall Impact
Government Initiatives
COVID-19 Impact on the Market

5. Global Neurological Biomarkers Market, By Biomarker Type, 2019 - 2031, (USD Bn)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
Artificial Tears
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Imaging Biomarkers
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Metabolomics Biomarkers
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Proteomic Biomarkers
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Genomics Biomarkers
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

6. Global Neurological Biomarkers Market, By Application, 2019 - 2031, (USD Bn)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
Alzheimer's Disease
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Parkinson's Disease
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Multiple Sclerosis
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Autism Spectrum Disorders
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

7. Global Neurological Biomarkers Market, By End User, 2019 - 2031, (USD Bn)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
Hospital Laboratories
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Clinical Diagnostic Centers
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Research Organizations
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

8. Global Neurological Biomarkers Market, By Region, 2019 - 2031, (USD Bn)

Introduction
- Market Share Analysis, By Region, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, For Region, 2019-2031
- Regional Trends
  - North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Biomarker Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Biomarker Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Biomarker Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Biomarker Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Biomarker Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
  - GCC
  - Israel
  - Rest of Middle East
  - Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Biomarker Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019 - 2031, (USD Bn)
  - North Africa
  - Central Africa
  - South Africa

9. Competitive Landscape

Company Profiles
- Thermo Fisher Scientific Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Merck & Co., Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Bio-Rad Laboratories, Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- AbbVie Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- QIAGEN N.V.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- F. Hoffmann-La Roche Ltd
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Siemens Healthineers AG
- Myriad RBM
- Quanterix Corporation
- PerkinElmer Inc.
- Fujirebio
- Alzheon, Inc.
- Diagenic ASA
- Psynova Neurotech Ltd
- Banyan Biomarkers, Inc.
- Cisbio Bioassays
- Athena Diagnostics
- Immuno-Biological Laboratories Co., Ltd.